» Articles » PMID: 20307711

Autologous and Allogeneic Cellular Therapies for High-risk Pediatric Solid Tumors

Overview
Specialty Pediatrics
Date 2010 Mar 24
PMID 20307711
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Since the 1950s, the overall survival of children with cancer has gone from almost zero to approaching 80%. Although there have been notable successes in treating solid tumors such as Wilms tumor, some childhood solid tumors have continued to elude effective therapy. With the use of megatherapy techniques such as tandem transplantation, dose escalation has been pushed to the edge of dose-limiting toxicities, and any further improvements in event-free survival will have to be achieved through novel therapeutic approaches. This article reviews the status of autologous and allogeneic hematopoietic stem cell transplantation (HSCT) for many pediatric solid tumor types. Most of the clinical experience in transplant for pediatric solid tumors is in the autologous setting, so some general principles of autologous HSCT are reviewed. The article then examines HSCT for diseases such as Hodgkin disease, Ewing sarcoma, and neuroblastoma, and the future of cell-based therapies by considering some experimental approaches to cell therapies.

Citing Articles

Effect of tandem autologous stem cell transplantation on survival in pediatric patients with high-risk solid tumors in South China.

Luo Z, Fan L, Guo W, Yang J, Li Z, Huang Y World J Stem Cells. 2025; 17(2):100621.

PMID: 40061267 PMC: 11885945. DOI: 10.4252/wjsc.v17.i2.100621.


The impact of NKG2A and NKG2D receptors and HLA-E and MICA ligands polymorphisms on post-transplant complications after paediatric allogeneic HSCT: a single-centre experience.

Siemaszko J, Ussowicz M, Rybka B, Ryczan-Krawczyk R, Kalwak K, Bogunia-Kubik K Front Genet. 2023; 14:1186123.

PMID: 37351346 PMC: 10282657. DOI: 10.3389/fgene.2023.1186123.


Haploidentical hematopoietic stem cell transplantation as individual treatment option in pediatric patients with very high-risk sarcomas.

Eichholz T, Doring M, Giardino S, Gruhn B, Seitz C, Flaadt T Front Oncol. 2023; 13:1064190.

PMID: 36895486 PMC: 9990259. DOI: 10.3389/fonc.2023.1064190.


Single-cell RNA profiling identifies diverse cellular responses to EWSR1/FLI1 downregulation in Ewing sarcoma cells.

Khoogar R, Li F, Chen Y, Ignatius M, Lawlor E, Kitagawa K Cell Oncol (Dordr). 2022; 45(1):19-40.

PMID: 34997546 PMC: 10959445. DOI: 10.1007/s13402-021-00640-x.


Aggressive Neuroblastoma in a Pediatric Patient with Severe Hemophilia A.

Costa L, Couto M, Moutinho J, Ferreira A, Costa E, Roncon S Pediatr Rep. 2021; 13(1):125-130.

PMID: 33800180 PMC: 8006017. DOI: 10.3390/pediatric13010018.


References
1.
Seeger R, Vo D, Ugelstad J, Reynolds C . Removal of neuroblastoma cells from bone marrow with monoclonal antibodies and magnetic immunobeads. Prog Clin Biol Res. 1986; 211:285-93. View

2.
Ladenstein R, Lasset C, Hartmann O, Klingebiel T, Bouffet E, Gadner H . Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant. 1994; 14(1):37-46. View

3.
ZETTERQUIST H, Hentschke P, Thorne A, Wernerson A, Mattsson J, Uzunel M . A graft-versus-colonic cancer effect of allogeneic stem cell transplantation. Bone Marrow Transplant. 2002; 28(12):1161-6. DOI: 10.1038/sj.bmt.1703287. View

4.
George R, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger R . High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006; 24(18):2891-6. DOI: 10.1200/JCO.2006.05.6986. View

5.
Crist W, Gehan E, Ragab A, Dickman P, Donaldson S, Fryer C . The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995; 13(3):610-30. DOI: 10.1200/JCO.1995.13.3.610. View